Merdad Parsey

Merdad Parsey

DirectoratGilead Sciences· In proxies 2019–2025

Pay in FY2024-3% from the year before · Gilead Sciences stock +14.0% the same year

Merdad Parsey was paid $8.1M in FY2024 (Dec), down 3%. Gilead Sciences stock rose 14.0% that year.

Pay$100 in the stock at the end of FY18 → $174
Pay is from the Summary Compensation Table of each Gilead Sciences proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. ArdelyxPublic company · 2 yr
    • Director2024 – Present · 2 yrNo stock prices for these years
  2. Gilead SciencesPublic company · 7 yr
    • M.D., Ph.D. Chief Medical Officer2019 – Present · 7 yrStock in role +210%
  3. Arrivent BiopharmaPublic company
    • Director? – PresentNo stock prices for these years
  4. Arcus Biosciences, Inc.Public company
    • Director? – PresentNo stock prices for these years

Roles come from the proxy statements of each company.

Boards1

  • ArdelyxDirector · -1 yr on the boardIndependentNominating and Corporate Governance—Paid as an executive

Board seats come from each company's latest proxy statement.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?